| __timestamp | MiMedx Group, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 90480000 | 612613000000 |
| Thursday, January 1, 2015 | 133384000 | 650773000000 |
| Friday, January 1, 2016 | 179997000 | 619061000000 |
| Sunday, January 1, 2017 | 220119000 | 628106000000 |
| Monday, January 1, 2018 | 258528000 | 717599000000 |
| Tuesday, January 1, 2019 | 198205000 | 964737000000 |
| Wednesday, January 1, 2020 | 181022000 | 875663000000 |
| Friday, January 1, 2021 | 198359000 | 886361000000 |
| Saturday, January 1, 2022 | 208789000 | 997309000000 |
| Sunday, January 1, 2023 | 211124000 | 1053819000000 |
| Monday, January 1, 2024 | 1053819000000 |
Data in motion
In the ever-evolving pharmaceutical landscape, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Takeda Pharmaceutical Company Limited and MiMedx Group, Inc. over the past decade.
Takeda, a global leader, has seen its SG&A expenses grow by approximately 72% from 2014 to 2023, reflecting its strategic expansions and acquisitions. Notably, 2023 marked a peak with expenses reaching over 1 trillion yen, underscoring its commitment to innovation and market presence.
Conversely, MiMedx, a smaller player, experienced a 133% increase in SG&A expenses, highlighting its aggressive market penetration strategies. Despite a dip in 2019, the company rebounded, maintaining a steady upward trajectory.
This comparative insight into SG&A expenses offers a window into the strategic priorities and market dynamics of these two distinct pharmaceutical entities.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Takeda Pharmaceutical Company Limited
Operational Costs Compared: SG&A Analysis of Pfizer Inc. and Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared
Takeda Pharmaceutical Company Limited vs Ascendis Pharma A/S: SG&A Expense Trends
Takeda Pharmaceutical Company Limited vs Opthea Limited: SG&A Expense Trends
Takeda Pharmaceutical Company Limited vs Viridian Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs MiMedx Group, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Viking Therapeutics, Inc. or MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Rhythm Pharmaceuticals, Inc. and MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Ligand Pharmaceuticals Incorporated and MiMedx Group, Inc.
Who Optimizes SG&A Costs Better? Wave Life Sciences Ltd. or MiMedx Group, Inc.
Cost Management Insights: SG&A Expenses for Celldex Therapeutics, Inc. and MiMedx Group, Inc.